Clinical trials: Vaccine Prophylaxis
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)
This is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of inactivated VZV vaccine for the prevention of HZ and HZ-related complications in adult recipients of autologous hematopoietic cell…
- Trial name
- NCT01229267
- Testing
- V212
- Volunteers
- 1,257 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection, Human Immunodeficiency Virus
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndrome).
- Trial name
- NCT00187044
- Testing
- PolyEnv1 vaccine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Human Papilloma Virus, Vaccine-Preventable Diseases
Hashtag HPV: HPV Vaccine Twitter Education Program
Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts…
- Trial name
- NCT05204030
- Testing
- HPV Twitter Education Program - Narrative, HPV Twitter Education Program - Non-Narrative
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Arkansas, Fayetteville
Prophylaxis of Ross River Virus Infection
Ross River Virus (RRV) Vaccine Study
The purpose of the study is to verify the safety and adequacy of the immune response produced by a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine and to demonstrate the consistency of manufacture…
- Trial name
- NCT01242670
- Testing
- Ross River Virus Vaccine
- Where
- 17 sites in Australia
- Volunteers
- 1,968 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
HIV
Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.
- Trial name
- NCT02366013
- Testing
- rcAd26.MOS1.HIV-Env 1x10^8 vp, rcAd26.MOS1.HIV-Env 1x10^9 vp, rcAd26.MOS1.HIV-Env 1x10^10 vp
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Prevention of Influenza
Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults
This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that…
- Trial name
- NCT03160118
- Testing
- Seasonal,quadrivalent,influenza vaccine
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Fever
Acetaminophen Before Vaccines for Infants Study (AVIS)
The purpose of this study is to see whether giving acetaminophen (the medicine in Tylenol) for routine infant vaccinations is helpful in preventing fever or other symptoms.
- Trial name
- NCT00325819
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy Volunteers, Haemophilus Influenzae Type b, Prevention
Phase III Study of Intramuscular TAK-816 in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of intramuscular TAK-816 in healthy Japanese infants.
- Trial name
- NCT02074345
- Testing
- TAK-816
- Where
- 4 sites in Japan
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Takeda
Rabies Infection
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
Demonstrate non-inferiority of the immune response between new versus the currently recommended intradermal regimens of rabies vaccine when administered with or without rabies immunoglobulins in healthy subjects ≥ 1 years of age.
- Trial name
- NCT02177032
- Testing
- Rabies vaccine, Rabies vaccines + Rabies immunoglobulins
- Where
- 6 sites in Philippines, Thailand
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
This study will evaluate the preventive vaccine efficacy, safety, and tolerability of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 in HIV-seronegative South African adults over 24 months and potentially up to 36 months…
- Trial name
- HVTN702 (NCT02968849)
- Testing
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59
- Where
- 14 sites in South Africa
- Volunteers
- 5,404 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.
- Trial name
- FluMist (NCT03158038)
- Testing
- Monovalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
Tuberculosis Infection
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years.
- Trial name
- NCT05945498
- Testing
- TB/Flu-05E vaccine
- Where
- Russia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Tatyana Zubkova
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19
The objective of the clinical study is to evaluate the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona vaccine in volunteers aged 18 and above.
- Trial name
- NCT04780035
- Testing
- EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- Where
- 8 sites in Russia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Lung Carcinoma
Testing the SurVaxM Vaccine for Lung Cancer Prevention
This phase II trial tests how well a survivin peptide vaccine called SurVaxM works in preventing lung cancer in high risk patients.
- Trial name
- NCT07169617
- Testing
- Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Severe Acute Respiratory Infection
Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults
This study assesses the seasonal of influenza vaccine effectiveness in adults hospitalised with laboratory-confirmed influenza through a network of hospitals in France.
- Trial name
- FLUVAC EV-03 (NCT02027233)
- Testing
- nasopharyngeal sample
- Where
- France
- Volunteers
- 6,173 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation